Mortality in the beta blocker heart attack trial: circumstances surrounding death.
In the Beta Blocker Heart Attack Trial, a double blind, randomized, controlled study, patients taking propranolol (180 or 240 mg/day) initiated 5-21 days post myocardial infarction had 26% fewer deaths than those taking placebo over a 25 month (mean) followup. Detailed analysis of the circumstances surrounding the BHAT deaths failed to reveal any striking difference between propranolol and placebo in the type of clinical event preceding death, the incidence and type of acute and prodromal signs and symptoms, the location of death, the activity preceding death or the percentage of deaths that were sudden or instantaneous, suggesting that propranolol may exert an "across the board" effect and improve survival by a combination of mechanisms. An unexpected finding was that the protective effect of propranolol appeared to occur during the hours of 10 p.m. to 7 a.m.
D000368:Aged; D002318:Cardiovascular Diseases / Q000150:complications / Q000401:mortality; D002986:Clinical Trials as Topic; D003645:Death, Sudden / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality* / Q000517:prevention & control; D011433:Propranolol / Q000627:therapeutic use*; D011897:Random Allocation; D012008:Recurrence; D013997:Time Factors
D011433:Propranolol